Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas

Neuro-Oncology

Volumn 16, Issue 7, 2014, Pages 914-923

  Sabha, Nesrin ^a   Knobbe, Christiane B ^c   Maganti, Majula ^c   Al Omar, Soha ^b   Bernstein, Mark ^b   Cairns, Rob ^c   Çako, Besmira ^f   Von Deimling, Andreas ^d   Capper, David ^d   Mak, Tak W ^c   Kiehl, Tim Rasmus ^e,f   Carvalho, Philippe ^b   Garrett, Evelyn ^g   Perry, Arie ^g   Zadeh, Gelareh ^a   Guha, Abhijit ^a,b   Croul, Sidney ^e,f  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UCSF Department of Medicine NCIRE   (United States)

Author keywords

IDH; low grade glioma; mutations; overall survival; progression free rate

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ISOCITRATE DEHYDROGENASE; PTEN PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GLIOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; MOLECULAR GENETICS; NEUROSURGERY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN PROTEIN INTERACTION; RISK FACTOR; TISSUE MICROARRAY; TUMOR VOLUME; BRAIN TUMOR; CANCER GRADING; CHROMOSOME 1; CHROMOSOME 19; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; GENOTYPE; KAPLAN MEIER METHOD; MALE; MORTALITY; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PTEN PHOSPHOHYDROLASE; SEQUENCE DELETION; TISSUE ARRAY ANALYSIS;

EID: 84902500037     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not299     Document Type: Article

References (26)

1. Louis DN, Ohgaki H, Wiestler OD, et al. (eds). WHO Classification of Tumours of the Central Nervous System. Lyon, France:IARC press, 2007.
2. Chang EF, Clark A, Jensen RL, et al. Multiinstitutional validation of the University of California at San Francisco low-grade glioma prognostic scoring system. J Neurosurg. 2009;111:203-210.
3. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479.
4. von Deimling A, von Ammon K, Schoenfeld D, et al. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol. 1993;3:19-26.
5. Kim Y-H, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol. 2010;177(6):2708-2714.
6. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361:1058-1066.
7. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807-1812.
8. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
9. Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology. 2009;73:1792-1795.
10. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosisthan IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120:707-718.
11. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 2010;75:1560-1566.
12. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16:1597-1604.
13. Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009;118:599-601.
14. Perry A, Miller CR, Gujrati M, et al. Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol. 2009;19:81-90.
15. Hartmann C, Mueller W, Lass U, et al. Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol. 2005;64:10-14.
16. Metellus P, Coulibaly B, Colin C, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol. 2010;120: 719-729.
17. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early eventsinthe developmentofastrocytomas and oligodendrogliomas. Am J Pathol. 2009;174:1149-1153.
18. Horbinski C, Kelly L, Nikiforov YE, et al. Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn. 2010;12:487-492.
19. Birner P, Toumangelova-Uzeir K, Natchev S, et al. Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression. Folia Neuropathol. 2011;49:88-93.
20. Preusser M, Wöhrer A, Stary S, et al. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol. 2011;70:715-723.
21. Gorovets D, Kannan K, Shen R, et al. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res. 2012;18:2490-2501.
22. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathol. 2009;118:469-474.
23. Hartmann C, Hentschel B, Tatagiba M, et al. for the German Glioma Network. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res. 2011;17:4588-4599.
24. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009;27:5743-5750.
25. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11:341-347.
26. Mukasa A, Takayanagi S, Saito K, et al. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Sci. 2012;103:587-592.